The Neurogenic Locus Notch Homolog Protein 1 pipeline drugs market research report outlays comprehensive information on the Neurogenic Locus Notch Homolog Protein 1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Neurogenic Locus Notch Homolog Protein 1 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, Metabolic Disorders, Hematological Disorders, and Central Nervous System which include the indications Oncology, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Type 1 Diabetes (Juvenile Diabetes), Hematological Disorders, and Multiple Sclerosis. It also reviews key players involved in Neurogenic Locus Notch Homolog Protein 1 targeted therapeutics development with respective active and dormant or discontinued products.
The Neurogenic Locus Notch Homolog Protein 1 pipeline targets constitutes close to eight molecules. Out of which, approximately five molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase I, Preclinical, and Discovery stages are 1, 2, and 2 respectively. Similarly, the universities portfolio in Preclinical, and Discovery comprises 2, and 1 molecule.
Neurogenic Locus Notch Homolog Protein 1 overview
Neurogenic Locus Notch Homolog Protein 1, abbreviated as NOTCH1, is a transmembrane receptor that belongs to the Notch family of proteins. NOTCH1 is a critical component of a highly conserved signaling pathway that plays diverse roles in cellular processes such as embryonic development, tissue maintenance, and cell differentiation. As a transmembrane receptor, NOTCH1 spans the cell membrane, allowing for communication between neighbouring cells. The NOTCH1 signalling pathway is initiated when NOTCH1 interacts with ligands, such as Delta-like ligands (DLL) and Jagged ligands, presented on the surface of adjacent cells. This interaction triggers a series of proteolytic cleavages that ultimately release the intracellular domain of NOTCH1 (NICD). Once liberated, NICD translocate to the nucleus, where it forms a complex with transcriptional coactivators. This complex regulates the expression of target genes, influencing cell fate decisions and various physiological processes. NOTCH1 is particularly known for its role in neurogenesis, where it contributes to the formation and maintenance of neural tissues. Additionally, NOTCH1 signaling is involved in the determination of cell fate in various tissues, including the cardiovascular system, immune system, and epithelial tissues. Dysregulation of the NOTCH1 pathway has been implicated in various human diseases, including certain types of cancer.
For a complete picture of Neurogenic Locus Notch Homolog Protein 1’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
